Third, hematologic toxicities such as neutropenia and thrombocytopenia remain the most common dose-limiting adverse events of PLK1 inhibitors and may restrict their use in combination with other myelosuppressive agents, including platinum and paclitaxel. Here, PLK1 is linked to Decreased total neutrophil count.